Centessa Pharmaceuticals plc financial data

Symbol
CNTA on Nasdaq
Location
3 Rd Floor, 1 Ashley Road, Altrincham, Cheshire, United Kingdom
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.27K % +26.5%
Debt-to-equity 35.2 % -24.7%
Return On Equity -56.5 % +10.5%
Return On Assets -41.8 % +2.82%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 134M shares +18.3%
Common Stock, Shares, Outstanding 134M shares +18.3%
Entity Public Float 622M USD +100%
Common Stock, Value, Issued 363K USD +17.5%
Weighted Average Number of Shares Outstanding, Basic 134M shares +22.1%
Weighted Average Number of Shares Outstanding, Diluted 134M shares +22.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
General and Administrative Expense 50.5M USD +3.1%
Operating Income (Loss) -206M USD -32.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -227M USD -43.5%
Income Tax Expense (Benefit) 3.83M USD +10.4%
Net Income (Loss) Attributable to Parent -230M USD -46.4%
Earnings Per Share, Basic -1 USD/shares -19.2%
Earnings Per Share, Diluted -1 USD/shares -19.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 44.2M USD -65.3%
Other Assets, Current 1.62M USD -17.1%
Assets, Current 300M USD -15.5%
Deferred Income Tax Assets, Net 25.4M USD -11.3%
Property, Plant and Equipment, Net 733K USD -18.8%
Operating Lease, Right-of-Use Asset 10.5M USD -8.13%
Other Assets, Noncurrent 1.72M USD -27.8%
Assets 492M USD +23.4%
Accounts Payable, Current 5.69M USD +6.99%
Employee-related Liabilities, Current 4.05M USD -0.86%
Accrued Liabilities, Current 24M USD +12%
Liabilities, Current 29.7M USD +11%
Operating Lease, Liability, Noncurrent 7.94M USD -7.63%
Other Liabilities, Noncurrent 29K USD 0%
Liabilities 147M USD +31.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.59M USD -0.25%
Retained Earnings (Accumulated Deficit) -1.07B USD -27.6%
Stockholders' Equity Attributable to Parent 345M USD +20.2%
Liabilities and Equity 492M USD +23.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -57.2M USD -53.5%
Net Cash Provided by (Used in) Financing Activities 3.09M USD -70.6%
Net Cash Provided by (Used in) Investing Activities -222M USD -1427%
Common Stock, Shares Authorized 222M shares +20.6%
Common Stock, Shares, Issued 134M shares +18.3%
Common Stock, Par or Stated Value Per Share 0 GBP/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -278M USD -2734%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 44.2M USD -65.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.68M USD -33.5%
Deferred Tax Assets, Valuation Allowance 94.9M USD +29.6%
Deferred Tax Assets, Gross 124M USD +17.6%
Operating Lease, Liability 8.6M USD -6.03%
Depreciation 86K USD +132%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -230M USD -47%
Lessee, Operating Lease, Liability, to be Paid 13.2M USD -10.9%
Property, Plant and Equipment, Gross 1.66M USD +8.21%
Operating Lease, Liability, Current 656K USD +18.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.7M USD +1.98%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.67M USD +2.02%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Deferred Income Tax Expense (Benefit) 995K USD +129%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.61M USD -18.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.73M USD +2%
Deferred Tax Assets, Operating Loss Carryforwards 96.4M USD +24.5%
Unrecognized Tax Benefits 2.61M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.77M USD +2.02%
Operating Lease, Payments 408K USD +2%
Additional Paid in Capital 1.41B USD +25.7%
Depreciation, Depletion and Amortization 217K USD -9.58%
Deferred Tax Assets, Net of Valuation Allowance 29.3M USD -9.52%
Share-based Payment Arrangement, Expense 32.6M USD +2.71%
Interest Expense 10.1M USD +24.2%